Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia (Q83362579)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16706552%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

review article

1 reference

title

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16706552%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

Risto S Cvetković

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16706552%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Caroline M Perry

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16706552%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16706552%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16706552%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16706552%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16706552%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

791-820

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16706552%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003495-200666060-00005

21 January 2020

exact match

0 references

cites work

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

12 December 2020

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

12 December 2020

Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma

1 reference

12 December 2020

Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation

1 reference

12 December 2020

Cancer statistics, 2005

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

12 December 2020

1 reference

12 December 2020

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

1 reference

12 December 2020

Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.

1 reference

12 December 2020

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia

1 reference

12 December 2020

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

1 reference

12 December 2020

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

12 December 2020

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

12 December 2020

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

12 December 2020

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study

1 reference

12 December 2020

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

1 reference

12 December 2020

Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.

1 reference

12 December 2020

Guidelines on the diagnosis and management of chronic lymphocytic leukaemia

1 reference

12 December 2020

Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells

1 reference

12 December 2020

Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy

1 reference

12 December 2020

Intensive chemotherapy with rituximab is safe and effective in AIDS non-Hodgkin's lymphoma

1 reference

12 December 2020

Rituximab Improves Rate and Duration of Chemotherapy-Induced Remissions in Indolent and Aggressive Non-Hodgkin's Lymphoma.

1 reference

12 December 2020

Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials.

1 reference

12 December 2020

Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas

1 reference

12 December 2020

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

12 December 2020

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

12 December 2020

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

1 reference

12 December 2020

Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia

1 reference

12 December 2020

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

12 December 2020

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

12 December 2020

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

12 December 2020

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

12 December 2020

The best treatment for diffuse large B-cell lymphoma: a German perspective.

1 reference

12 December 2020

Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis

1 reference

12 December 2020

Clinical staging of chronic lymphocytic leukemia

1 reference

12 December 2020

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

12 December 2020

Quality of life in patients with low-grade non-Hodgkin's lymphoma.

1 reference

12 December 2020

Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

1 reference

12 December 2020

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

1 reference

12 December 2020

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

1 reference

12 December 2020

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

12 December 2020

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

1 reference

12 December 2020

The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia

1 reference

12 December 2020

Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands

1 reference

12 December 2020

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

1 reference

12 December 2020

Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.

1 reference

12 December 2020

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

1 reference

12 December 2020

Lymphoma: diagnosis, staging, natural history, and treatment strategies

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

When and how to treat chronic lymphocytic leukemia

1 reference

12 December 2020

Systematic overview of cost-utility assessments in oncology

1 reference

12 December 2020

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.

1 reference

12 December 2020

Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective.

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

12 December 2020

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases

1 reference

12 December 2020